Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORH-2014 in Advanced Hematological Disorders
NCT03048344Phase 1Completed
- Sponsor
- Orsenix
- Start
- Dec 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Arsenol in acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS) and 2 more (2 arms), sponsored by Orsenix. Primary endpoints: Recommended Dose of ORH-2014 at Week 4 and Number of Participants With Adverse Events at Week 28. Started Dec 2016; status: completed.
02
Drugs
Arsenol
03
Conditions
acute myeloid leukemia (AML)acute promyelocytic leukemia (APL)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03048344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03048344.